This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Sources searched to identify primary studies
Not stated.
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
Individual data and summary statistics from individual studies.
Number of primary studies included
At least 27 studies were included.
Methods of combining primary studies
Meta-analysis in some cases, narrative in others.
Investigation of differences between primary studies
Results of the review
The use of EPO was found to reduce exposure to allogeneic blood with odds ratios of 0.38 (95% CI: 0.24 -0.63) for EPO alone and 0.42 (95% CI: 0.28 -0.62) for EPO to augment PAD.
EPO alone reduced the mean number of units received by 57.5% (from 1.27 to 0.54 units per patient). EPO to augment PAD reduced the mean number of units received by 25.7% (from 0.35 to 0.26 units per patient).
For HIV, hepatitis B and hepatitis C, the base case risks per unit of allogeneic blood transfused were 2/1000000, 16/1000000 and 10/1000000. The risks of haemolytic transfusion reactions associated with all transfusions were 52.3/1000000 for a non-fatal reaction and 1.67/1000000 for a fatal reaction. These risks were assumed to be the same for both allogeneic and autologous blood.
The risk of a febrile reaction was estimated to be 1/100 units. For patients who did not contract any transfusion-related infections, the discounted life expectancy was estimated to be 13.04 years. The estimate of the discounted life expectancies for Canadian patients with HIV was 8.47 years, for hepatitis B was 12.97 years and for hepatitis C was 12.96 years.
These values were used as the principal input parameters to the model.
Measure of benefits used in the economic analysis
The measure of benefit was the number of life-years gained. Outcomes were discounted at an annual rate of 5%.
Direct costs
Direct costs were discounted at an annual rate of 5%. Quantities and costs were not reported separately. Direct costs included the costs of EPO, the costs of allogeneic and autologous blood collection and delivery, the costs associated with transfusion-related illnesses (hepatitis B and C, HIV, haemolytic reactions and febrile reactions). The quantity/cost boundary adopted was that of the health service. The estimation of quantities and costs was based on actual data. The list price of EPO was obtained from the pharmacy department of the Ottawa Civic Hospital. Other cost estimates were derived from published studies. The price year was 1996.
